Tactical Therapeutics, Inc

Tactical Therapeutics, Inc is a private clinical stage company in New York, NY, developing a First-in-Class Inhibitor of Calcium Signaling and Calcium Channels, to treat difficult to treat solid cancers including Glioblastoma. Three Phase I trials have been completed of the lead drug, Carboxyamidotriazole Orotate (CTO) in 44 advanced cancer patients and 42 GBM patients. End-of Phase 1 meeting has been held with FDA. CTO has shown safety and efficacy in Phase IB. Registration randomized Phase 2 trial is planned in recurrent GBM patients on the Orphan Designation Fast track. Series B raise is being done to fund this. Intellectual Property is 8 US patents, 75 international patents.